电邮这篇文章 Dannye dolgosrochnogo nablyudeniya podtverzhdayut, chto razrabotannyy kompaniey Novartispreparat TasignaR prevoskhodit preparat GlivekR po snizheniyu riska progressirovaniyazabolevaniya u patsientov s vpervye diagnostirovannym khronicheskim mieloleykozom
- 作者: - -
- 期: 卷 13, 编号 1 (2011)
- 页面: 7-8
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29421
- ID: 29421
如何引用文章
